We have located links that may give you full text access.
Efficacy and safety of histamine H 4 receptor antagonist ZPL-3893787 in atopic dermatitis.
Journal of Allergy and Clinical Immunology 2018 November 9
BACKGROUND: Histamine 4 (H4 ) receptor antagonists are potential novel treatments for inflammatory skin diseases including atopic dermatitis (AD).
OBJECTIVE: To study the efficacy and safety of ZPL-3893787 (selective H4 receptor antagonist) in moderate/severe AD.
METHODS: A randomised, double-blind, placebo-controlled, parallel-group study was conducted to evaluate ZPL-3893787 (30mg) once daily oral therapy in adult patients with moderate/severe AD. Patients were randomized (2:1), to ZPL-3893787 (n=65) or placebo (n=33) for 8 weeks. Patients had a history of AD for >12 months, Eczema Area and Severity Index (EASI) of ≥12 and ≤48, Investigator's Global Assessment (IGA) ≥3, pruritus score of ≥5 (0-10 scale) and AD of ≥10% body surface area (BSA). Efficacy parameters included EASI, IGA, SCORing Atopic Dermatitis (SCORAD), and pruritus assessment.
RESULTS: Treatment with oral ZPL-3893787 showed a 50% reduction in EASI score compared to 27% for placebo. The placebo-adjusted reduction in EASI score at Week 8 was 5.1; 1-sided p=0.01. Clear or almost-clear IGA scores were 18.5% with ZPL-3893787 vs placebo 9.1%. SCORAD exhibited 41% reduction with ZPL-3893787 vs 26% placebo (placebo-adjusted reduction of 10.0; p=0.004). There was a 3-point reduction (scale 1-10) in pruritus with ZPL-389, but there was a similar reduction with placebo, resulting in a non-significant difference (p=0.249). Patient reported pruritus subscore obtained from SCORAD was reduced with ZPL-3893787 compared to placebo at Week 8 (non-significant). ZPL-3893787 was well tolerated.
CONCLUSION: These results showed for the first time that ZPL-3893787 improved inflammatory skin lesions in patients with AD, confirming H4 receptor antagonism as a novel therapeutic option.
OBJECTIVE: To study the efficacy and safety of ZPL-3893787 (selective H4 receptor antagonist) in moderate/severe AD.
METHODS: A randomised, double-blind, placebo-controlled, parallel-group study was conducted to evaluate ZPL-3893787 (30mg) once daily oral therapy in adult patients with moderate/severe AD. Patients were randomized (2:1), to ZPL-3893787 (n=65) or placebo (n=33) for 8 weeks. Patients had a history of AD for >12 months, Eczema Area and Severity Index (EASI) of ≥12 and ≤48, Investigator's Global Assessment (IGA) ≥3, pruritus score of ≥5 (0-10 scale) and AD of ≥10% body surface area (BSA). Efficacy parameters included EASI, IGA, SCORing Atopic Dermatitis (SCORAD), and pruritus assessment.
RESULTS: Treatment with oral ZPL-3893787 showed a 50% reduction in EASI score compared to 27% for placebo. The placebo-adjusted reduction in EASI score at Week 8 was 5.1; 1-sided p=0.01. Clear or almost-clear IGA scores were 18.5% with ZPL-3893787 vs placebo 9.1%. SCORAD exhibited 41% reduction with ZPL-3893787 vs 26% placebo (placebo-adjusted reduction of 10.0; p=0.004). There was a 3-point reduction (scale 1-10) in pruritus with ZPL-389, but there was a similar reduction with placebo, resulting in a non-significant difference (p=0.249). Patient reported pruritus subscore obtained from SCORAD was reduced with ZPL-3893787 compared to placebo at Week 8 (non-significant). ZPL-3893787 was well tolerated.
CONCLUSION: These results showed for the first time that ZPL-3893787 improved inflammatory skin lesions in patients with AD, confirming H4 receptor antagonism as a novel therapeutic option.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app